Corporate Governance Report: Enhancement of Governance Structure with New Audit and Nomination Committees, Improved Dividend Predictability
Daewoong Pharma strengthened governance by establishing an Audit Committee and Outside Director Nomination Committee upon becoming a large listed company (assets over 2 trillion KRW) in April 2026.
Amended articles to enhance dividend predictability: record date for dividends can be set after dividend decision, allowing shareholders to know dividend amount before buying shares.
Stable shareholder structure with top shareholder holding 61.33%; consistent cash dividend of 600 KRW per share for three consecutive years.
Board comprises 3 inside and 4 outside directors (majority), with all outside directors serving on the Audit Committee.
Implements electronic voting, avoids peak shareholder meeting dates, and maintains a CEO succession policy.
Operates robust internal control systems including compliance program (CP) and ISO 37001 anti-bribery certification.
No separate value-up plan disclosed yet, but communication with investors is ongoing through IR activities.
[AI Summary]This governance report reflects Daewoong Pharma's proactive efforts to enhance shareholder value through improved dividend predictability and strengthened oversight with the establishment of an Audit Committee and Nomination Committee. These structural improvements, coupled with consistent dividend payments, are positive for long-term investors and support share price stability.